Versartis Inc. (NASDAQ:VSAR) has been given a consensus recommendation of “Hold” by the seven research firms that are currently covering the stock. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation and four have issued a buy recommendation on the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $20.67.

VSAR has been the topic of several recent research reports. Credit Suisse Group AG reaffirmed a “sell” rating and set a $11.00 target price on shares of Versartis in a research note on Monday. Zacks Investment Research cut shares of Versartis from a “buy” rating to a “hold” rating in a research note on Saturday, August 13th. Canaccord Genuity reaffirmed a “buy” rating and set a $28.00 target price on shares of Versartis in a research note on Friday, July 29th. Finally, Citigroup Inc. set a $23.00 target price on shares of Versartis and gave the stock a “buy” rating in a research note on Thursday, August 11th.

Versartis (NASDAQ:VSAR) traded up 6.7154% on Tuesday, hitting $13.3501. 51,831 shares of the stock were exchanged. The firm’s market cap is $394.38 million. The stock’s 50 day moving average price is $12.53 and its 200 day moving average price is $10.11. Versartis has a 52-week low of $6.17 and a 52-week high of $14.69.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/versartis-inc-nasdaqvsar-receives-consensus-rating-of-hold-from-analysts.html

Versartis (NASDAQ:VSAR) last announced its earnings results on Thursday, July 28th. The biopharmaceutical company reported ($0.75) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.78) by $0.03. Equities research analysts forecast that Versartis will post ($2.76) earnings per share for the current year.

In other news, CEO Jay Shepard sold 5,442 shares of Versartis stock in a transaction on Monday, August 22nd. The stock was sold at an average price of $12.88, for a total transaction of $70,092.96. Following the transaction, the chief executive officer now owns 155,358 shares in the company, valued at approximately $2,001,011.04. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 11.60% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Dimensional Fund Advisors LP raised its position in Versartis by 10.9% in the second quarter. Dimensional Fund Advisors LP now owns 20,388 shares of the biopharmaceutical company’s stock valued at $225,000 after buying an additional 1,999 shares in the last quarter. Nationwide Fund Advisors raised its stake in shares of Versartis by 4.2% in the second quarter. Nationwide Fund Advisors now owns 56,765 shares of the biopharmaceutical company’s stock valued at $628,000 after buying an additional 2,284 shares during the period. JPMorgan Chase & Co. raised its stake in shares of Versartis by 35.7% in the second quarter. JPMorgan Chase & Co. now owns 856,524 shares of the biopharmaceutical company’s stock valued at $9,473,000 after buying an additional 225,561 shares during the period. Oxford Asset Management raised its stake in shares of Versartis by 28.9% in the second quarter. Oxford Asset Management now owns 80,989 shares of the biopharmaceutical company’s stock valued at $896,000 after buying an additional 18,169 shares during the period. Finally, Emerald Acquisition Ltd. bought a new stake in shares of Versartis during the second quarter valued at about $547,000. Institutional investors and hedge funds own 69.09% of the company’s stock.

Versartis Company Profile

Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing long-acting recombinant human growth hormone (rhGH), somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s product pipeline includes VRS-317 and XTEN Technology.

5 Day Chart for NASDAQ:VSAR

Receive News & Ratings for Versartis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.